Defining the Optimal Dose of Atrasentan by Evaluating the Exposure-Response Relationships of Albuminuria and Bodyweight.

about

Defining the Optimal Dose of Atrasentan by Evaluating the Exposure-Response Relationships of Albuminuria and Bodyweight.

Item

http://www.wikidata.org/entity/Q51731812

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@en

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@nl

type

Item

label

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@en

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@nl

prefLabel

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@en

Defining the Optimal Dose of A ...... of Albuminuria and Bodyweight.

@nl

P1476

Determining the optimal dose o ...... of albuminuria and bodyweight

@en

P2093

Dick de Zeeuw

http://www.w3.org/2001/XMLSchema#string

Hans-Henrik Parving

http://www.w3.org/2001/XMLSchema#string

Nael M Mostafa

http://www.w3.org/2001/XMLSchema#string

P2860

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy

Avosentan for overt diabetic nephropathy.

Endothelin-1 inhibits sodium reabsorption by ET(A) and ET(B) receptors in the mouse cortical collecting duct

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy.

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.

Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.

Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET).

Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Baseline characteristics and enrichment results of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial.

P304

2019-2022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.13312

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jasper Stevens

Hiddo J L Heerspink

Jeroen V Koomen

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29603851

http://www.w3.org/2001/XMLSchema#string

P932

6055665

http://www.w3.org/2001/XMLSchema#string